Minimal important difference of the Migraine Disability Assessment (MIDAS): Longitudinal data from the DMKG Headache Registry
Cephalalgia · 2024
DOI: 10.1177/03331024241261077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cephalalgia, 2024. Verfasst von Ruth Ruscheweyh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, LMU University Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Migraine Disorders, Registries, Disability Evaluation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer Pharmaceuticals, H. Lundbeck A/S, Lilly Deutschland.
Abstract (Originalsprache)
Background
The Migraine Disability Assessment (MIDAS) is widely used. However, there are limited data on how much a reduction in the MIDAS score indicates a change that matters to the patient.
Methods
Data from the DMKG (i.e. German Migraine and Headache Society) Headache Registry were used to determine the minimal important difference (MID) of the MIDAS, using the Patient Global Impression of Change (PGIC) as anchor and applying average change and receiver operating characteristic curve methods.
Results
In total, 1218 adult migraine patients (85.6% female, 40.2 ± 12.8 years, baseline MIDAS 44.2 ± 47.4, follow-up MIDAS 36.5 ± 45.3) were included. For patients with baseline MIDAS >20 (MIDAS grade IV, n = 757), different methods using PGIC “somewhat improved” as anchor yielded percent change MIDs of the MIDAS between −29.4% and −33.2%. For baseline MIDAS between 6 and 20 (grades II and III, n = 334), using PGIC “much improved” as anchor, difference change MIDs were between −3.5 and −4.5 points.
Conclusions
Based on the above results, we estimated the MID of the MIDAS at −30% for patients with a baseline MIDAS >20, and at −4 points for those with a baseline MIDAS of 6–20, for a tertiary headache care population. Trial Registration The DMKG Headache Registry is registered with the German Clinical Trials Register (DRKS 00021081).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, LMU University Hospital, LMU Munich, Munich, Germany.
- German Migraine and Headache Society, Frankfurt, Germany.
- Department of Neurology, Klinikum Passau, Passau, Germany.
- Headache Center Frankfurt, Frankfurt, Germany.
- Interdisciplinary Pain Center, University Hospital and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany.
- Department of Neurology, Headache Center North-East, University Medical Center Rostock, Rostock, Germany.
ORCID-Profile: Ruth Ruscheweyh, Gudrun Goßrau, Jörg Scheidt
Förderung
- Pfizer Pharmaceuticals
- H. Lundbeck A/S
- Lilly Deutschland
- Novartis Pharma
- Teva Pharmaceutical Industries
Zitieren
APA
Ruscheweyh, R., Förderreuther, S., Freilinger, T., Gaul, C., Goßrau, G., Jürgens, T. P., Kraya, T., Neeb, L., Ruschil, V., Scheidt, J., & Dresler, T. (2024). Minimal important difference of the Migraine Disability Assessment (MIDAS): Longitudinal data from the DMKG Headache Registry. Cephalalgia. https://doi.org/10.1177/03331024241261077
Vancouver
Ruscheweyh R, Förderreuther S, Freilinger T, Gaul C, Goßrau G, Jürgens TP, et al. Minimal important difference of the Migraine Disability Assessment (MIDAS): Longitudinal data from the DMKG Headache Registry. Cephalalgia. 2024. doi:10.1177/03331024241261077
BibTeX
@article{Ruscheweyh2024,
author = {Ruscheweyh, Ruth and Förderreuther, Stefanie and Freilinger, Tobias and Gaul, Charly and Goßrau, Gudrun and Jürgens, Tim Patrick and Kraya, Torsten and Neeb, Lars and Ruschil, Victoria and Scheidt, Jörg and Dresler, Thomas},
title = {Minimal important difference of the Migraine Disability Assessment (MIDAS): Longitudinal data from the DMKG Headache Registry},
journal = {Cephalalgia},
year = {2024},
doi = {10.1177/03331024241261077}
}
EUVIMED